UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Journal of clinical oncology, 2022-01, Vol.40 (2), p.161-170

2022

Volltextzugriff (PDF)

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

OncoTargets and therapy, 2018-01, Vol.11, p.7095-7107

2018

Volltextzugriff (PDF)

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature reviews. Clinical oncology, 2021-05, Vol.18 (5), p.313-319

2021

Volltextzugriff (PDF)

Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4922-4927

2006

Volltextzugriff (PDF)

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4040-4040

2020

Volltextzugriff (PDF)

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature reviews. Clinical oncology, 2021-05, Vol.18 (5), p.320-320

2021

Volltextzugriff (PDF)

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Clinical cancer research, 2005-06, Vol.11 (12), p.4338-4340

2005

Volltextzugriff (PDF)

Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors

Case reports in hematology, 2018-01, Vol.2018 (2018), p.1-4

2018

Volltextzugriff (PDF)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer

Case reports in oncology, 2017-12, Vol.10 (3), p.1098-1104

2017

Volltextzugriff (PDF)

Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

Journal of Oncology, 2009-01, Vol.2009 (2009), p.1-8

2009

Volltextzugriff (PDF)

A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma

Current pharmacogenomics and personalized medicine, 2015-06, Vol.12 (4), p.188-198

2015

Volltextzugriff (PDF)

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A724-A725

2023

Volltextzugriff (PDF)

636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A727-A728

2023

Volltextzugriff (PDF)

Management strategies in pancreatic cancer

American journal of health-system pharmacy, 2011-04, Vol.68 (7), p.573-584

2011

Volltextzugriff (PDF)

A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors

Clinical cancer research, 2007-04, Vol.13 (7), p.2109-2114

2007

Volltextzugriff (PDF)

Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2320-2326

2008

Volltextzugriff (PDF)

Phase I Trial of Imexon in Patients With Advanced Malignancy

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1779-1784

2007

Volltextzugriff (PDF)

Signal transduction pathways that regulate cell survival and cell death

Oncogene, 1998-12, Vol.17 (25), p.3207-3213

1998

Volltextzugriff (PDF)

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial

Cancer chemotherapy and pharmacology, 2007-07, Vol.60 (2), p.295-303

2007

Volltextzugriff (PDF)

Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4199-TPS4199

2023

Volltextzugriff (PDF)

Tumor treating fields (TTFields) concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: The phase 3 PANOVA-3 study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS770-TPS770

2023

Volltextzugriff (PDF)

PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4187-TPS4187

2022

Volltextzugriff (PDF)

PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS629-TPS629

2022

Volltextzugriff (PDF)

Abstract PO-051: PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma

Cancer research (Chicago, Ill.), 2021-11, Vol.81 (22_Supplement), p.PO-051-PO-051

2021

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(98)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(38)
Science & Technology
(38)
Humans
(33)
Oncology
(29)
Male
(20)
Middle Aged
(20)
Female
(18)
Aged
(16)
Tumors
(15)
Adult
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Aged, 80 And Over
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Pancreatic Neoplasms - Drug Therapy
(11)
Treatment Outcome
(11)
Pancreatic Cancer
(10)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(9)
Gemcitabine
(9)
Metastasis
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer

Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

Management strategies in pancreatic cancer

A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors

Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study

Phase I Trial of Imexon in Patients With Advanced Malignancy

Signal transduction pathways that regulate cell survival and cell death

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trial

Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer

Tumor treating fields (TTFields) concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: The phase 3 PANOVA-3 study

PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma

Abstract PO-051: PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma

Suchergebnisse filtern